stockrowAlamar Biosciences, Inc.
ALMRAlamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Revenue
- +68.5%
- EPS
- +72.0%
- Free cash flow
- +1.07%
Quarter to September 2026, against a year earlier
Follow ALMR
Alert me
Alamar Biosciences, Inc. (ALMR) Return on invested capital
Alamar Biosciences, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −38.9%, down 38.9 percentage points from fiscal 2025 (0.00%). That is below the Medical Devices industry median of −5.22% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| TMDX TransMedics Group, Inc. compare | 48.0% |
| UFPT UFP Technologies, Inc. compare | 11.2% |
| CNMD CONMED Corporation compare | 4.64% |
| INSP Inspire Medical Systems, Inc. compare | 1.97% |
| ESTA Establishment Labs Holdings Inc. compare | −5.22% |
| ENOV Enovis Corporation compare | −10.8% |
| ALMR Alamar Biosciences, Inc. | −38.9% |
| BFLY Butterfly Network, Inc. compare | −58.2% |
| NVCR NovoCure Limited compare | −106.1% |
| Medical Devices industry median | −5.22% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)